A75 COMPARISON OF TWO DIFFERENT ASSESSMENT TECHNIQUES FOR MEASUREMENT OF VEDOLIZUMAB TROUGH LEVELS IN ADULT PATIENTS WITH IBD

BACKGROUND: Vedolizumab (VLZ), an α4β7 integrin antagonist, is a therapeutic monoclonal antibody approved by Health Canada in 2017 for use in moderate to severe Crohn’s disease (CD) and ulcerative colitis (UC). Since loss of response to VLZ in patients with inflammatory bowel disease is likely due t...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Can Assoc Gastroenterol
Main Authors: Farrag, K, Berger, C, Armbruster, F, Schulze, H, Dignass, A, Stein, J
Formato: Artigo
Idioma:Inglês
Publicado em: Oxford University Press 2019
Assuntos:
Posters Of Distinction
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6512525/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/jcag/gwz006.074
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados